EUR/USD 1.13767
-0.081%
Gold 4017.51
-0.273%
Oil 83.384
6.452%
USD/JPY 163.787
-0.045%
GBP/USD 1.32826
-0.041%
GBP/JPY 217.557
-0.071%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
July 29th - Despite some speculation that the Federal Reserve might unexpectedly raise interest rates on Wednesday, Fundstrat Global Advisors market strategist Tom Lee believes this is unlikely, primarily based on recent progress on inflation. The latest inflation data shows that housing costs and other key components are slowing, giving the Fed room to keep rates unchanged. Therefore, it would be surprising if the Fed, which always emphasizes data collection, concluded that inflationary pressures remain strong based solely on surface observations. Admittedly, inflation has not yet returned to 2%, but the impact of tariffs and rising oil prices are distorting these figures. However, the Fed may consider further reducing its asset holdings on its balance sheet.TSMC (TSM.N): Raw material supply is normal.On July 29th, CSPC Pharmaceutical Group (01093.HK) announced in Hong Kong that its Phase II clinical trial (SYH2062-003) for the treatment of essential hypertension in adults, developed by the Group, has been officially launched at its first center in China. This product specifically silences the angiotensinogen (AGT) gene, inhibits the expression of the corresponding protein, and alleviates excessive activation of the renin-angiotensin system (RAAS), thereby exerting an effective pathway inhibition and long-term blood pressure control effect.On July 29, CSPC Pharmaceutical Group (01093.HK) announced in Hong Kong that CRB-701 (SYS6002), which the Group licensed to Corbus Pharmaceuticals, Inc. for development, has been approved by the U.S. Food and Drug Administration to initiate a registration clinical trial (trial code: TEMPO-1) for second-line treatment of oropharyngeal squamous cell carcinoma.Italian oil company Eni: Refineries will operate at maximum capacity in the third quarter.

Silver Price Analysis: XAG / USD reverses from a six-week-old resistance level toward $22.00

Daniel Rogers

Mar 20, 2023 13:19

 截屏2022-06-06 下午5.54.42.png

 

As the Fed week gets underway, the silver price (XAG / USD) accepts offers to renew intraday lows near $22.40, reversing from the greatest levels since early February.

 

In doing so, the brilliant metal reverses from the horizontal area consisting of multiple peaks marked since February 3 at approximately $22.60.

 

Notably, the overbought conditions of the RSI (14) aid the XAG/USD in trimming recent gains near the multi-day high.

 

However, optimistic Silver purchasers are buoyed by bullish MACD signals and the metal's sustained trading above critical support levels.

 

A one-week-old ascending trend line near $21.90 and the 200-bar Exponential Moving Average (EMA) near $21.65 provide immediate crucial support.

 

The early-month swing high near $21.30 and the $21.00 round figure can act as additional downside filters for XAG/USD bears before targeting the monthly low of $19.90.

 

In the meantime, the Silver price rise above the aforementioned resistance line near $22.60 requires confirmation from the 61.8% Fibonacci retracement level of the metal's February-March decline, which is located close to $22.85.

 

After that, a rise to the Year-To-Date (YTD) high around $24.65 cannot be ruled out.

 

Silver prices are expected to decline overall, but the bears have a long way to go before regaining control.


Suggestion